Chairman: Paul J. Mirabella

Mr. Mirabella is President and Chief Executive Officer of Naviscan, Inc. He joined Naviscan with 30 years of diagnostic imaging experience with GE Healthcare, where he held leadership roles in technology, marketing and global business management in ultrasound, computed tomography (CT), magnetic resonance, and sales and services. Mr. Mirabella holds four patents in CT and has participated in a variety of successful global product launches. Prior to joining Naviscan, he was President and CEO of Global Diagnostic Imaging, while retaining responsibility for the commercial leadership of sales, marketing, and services in the Americas. Mr. Mirabella obtained degrees in aerospace engineering and applied mechanics from Polytechnic Institute in New York and a Masters in mechanical engineering from the University of Central Florida. He is a graduate of the GE Business Management Program accredited by the University of Wisconsin-Whitewater.

Director: Timothy Mills, PhD

With over 25 years of experience in biomedical research, corporate management and venture investing, Dr. Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. Sanderling portfolio companies he previously served include Stereotaxis and Stentor, acquired by Royal Philips Electronics. Additionally, he is Chairman and CEO of Torax Medical, Taligen Therapeutics, Pulsar Vascular and Theregen and is a Director for CardioNet, Novostent, InfraReDx, and Triage Wireless. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics. Dr. Mills received his PhD in bioengineering from the University of California, Berkeley & San Francisco School of Medicine.

Director: Michael Ward

Mr. Ward is a partner at QuestMark and focuses on investments in both healthcare and information technology. He currently also serves on the boards of Vapotherm and MedManage Systems, and is actively involved with Nimblefish Technologies and GeneOhm Sciences. Prior to joining QuestMark, Mr. Ward was a management consultant with the Boston Consulting Group, where he worked with clients in the healthcare, telecom, and retail industries. Previously, he was an Intelligence Officer in the US Navy. Mr. Ward is a graduate of Northwestern University and received his MBA from Harvard Business School.

Director: Gina Dubbé

As a Managing Partner and co-founder of Walker Ventures, Ms. Dubbé is responsible for the selection and management of a $100M investment portfolio of early stage companies. Prior to the founding of Walker Ventures, Ms. Dubbé was a key part of the management team that led the IPO and sale of Trusted Information Systems. Ms. Dubbe has held key sales and engineering management positions with ORACLE Corporation, PRC Corporation, Interleaf Corporation and Arinc Research. Ms. Dubbé is a Licensed Professional Engineer with a Master's degree in engineering from George Washington University.

Director: Abhi Acharya, PhD

Dr. Acharya has over 30 years experience in the scientific and business aspects of the medical device field. His primary focus is in U.S. and international device laws, regulations, clinical trial strategies and product commercialization. Dr. Acharya previously held numerous senior level positions over a 16-year period beginning in 1977 at the U.S. Food and Drug Administration, including Director of the Division of Cardiovascular, Respiratory and Neurological Devices, where he directed the review and approval of PMA, IDE and 510(k) submissions during a period of rapid evolution for device technologies. Dr. Acharya sits on the Board of Directors of Stereotaxis (STXS), Neomend Inc., InfraRedX Inc., and Regen Biologics. He holds a B. Tech. degree in metallurgical engineering from the Indian Institute of Technology, Kharagpur, India, and an M.S. and PhD in biomaterials engineering from Northwestern University in Chicago, Illinois.

Director: André Cheng, MD, PhD

Dr. Cheng is the Senior Vice President for Healthcare at Height Analytics. He has extensive clinical and business experience related to reimbursement in the medical device industry. He has served as the Vice President of Medical Affairs and Reimbursement at Acclarent, Inc. After acquisition by Ethicon, Inc., a Johnson & Johnson company, he served as Worldwide vice President of Health Economics and Reimbursement. Prior to this, he was a Managing Partner for The Advisory Board Company. Dr. Cheng is a graduate of the Johns Hopkins School of Medicine and holds a PhD in Clinical Investigations and Healthcare Economics from the Johns Hopkins School of Public Health. 

Director: Ronald Schilling, PhD

Dr. Schilling has over 40 years of operating and general management experience in the medical device and technology industries. Most recently, Dr. Schilling was a General Partner at Mi3 Venture Partners, a venture capital investment fund for the imaging-related sector of the healthcare industry. He is President of RBS Consulting Inc., a firm specializing in strategic planning for biomedical imaging companies and not-for-profit organizations. Dr. Schilling has held various executive positions at Toshiba America Medical Systems, Diasonics, and General Electric Medical Systems. Dr. Schilling holds a PhD in electrical engineering from Polytechnic Institute of New York.

Secretary: Thomas Coll

Mr. Coll is a partner in the Cooley Godward Kronish Business department. He joined the firm in 1989, practicing in the San Francisco office until moving to San Diego as a founding member of that office in November 1991. Mr. Coll received a J.D. from the University of California, Berkeley School of Law, where he was a member of the Order of the Coif. He is a member of the State Bar of California, the American Bar Association and the San Diego County Bar Association. Mr. Coll was selected for the 2006 edition of The Best Lawyers in America for the Leveraged Buyouts and Private Equity Law category.